DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.

Author(s): Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM

Affiliation(s): Department of Emergency Medicine, Naval Medical Center, Portsmouth, Virginia, USA.

Publication date & source: 2005-07, J Emerg Med., 29(1):29-35.

Publication type: Clinical Trial; Randomized Controlled Trial

Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted. Patients were randomized to: LEV (<or=6 nebs LEV 1.25 mg); or RAC/IB (<or=3 nebs RAC 5.0 mg+IB 0.25 mg followed as needed by <or=3 nebs RAC 5.0 mg). No difference was noted in the study population (mean age 11.6 years and initial mean predicted PEF 49.5%) between LEV (n=72) and RAC/IB (n=68) for study outcomes except for measures of heart rate (HR). Median % HR increase for RAC/IB (26%) exceeded LEV (9%) (p<0.001). In a sample of children with acute asthma and initial mean PEF<50% predicted, LEV was associated with less tachycardia but had no other advantage over RAC combined with IB.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017